←
Dinesh V. Patel, PhD226 posts
Dinesh V. Patel, PhD avatar

Dinesh V. Patel, PhD

@ProtagonistCEO

CEO & President of Protagonist Therapeutics. 38 years of executive, entrepreneural, and scientific experience spanning big pharma & biotechs, and loving it!

◷ Joined February 2010
Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Oct 23

The Global approvals for #Icotyde continue to expand. Hearty Congrats to all involved in the journey. Cheers!

Protagonist is very pleased to see another global approval for ICOTYDE™ (icotrokinra)! ICOTYDE, co-discovered by Protagonist and Johnson & Johnson scientists, has now been approved in the United Kingdom for adults and adolescents with moderate-to-severe plaque psoriasis. This latest approval builds on approvals in the U.S., China, and EU, bringing ICOTYDE to more patients around the world. gov.uk/government/news/mhra-… #ICOTYDE #PeptideTherapeutics #PTGX

Post attachment
Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Oct 3

From Local to Global; gratifying to see #MIMRYLO reaching to patients globally. Big Congrats to our partner @TakedaPharma. A huge motivator for team @ProtagonistTx to keep doing what it does best; inventing new medicine to address unmet needs globally. Cheers!

MIMRYLO™ (rusfertide) has been approved in the United Arab Emirates for adults with Polycythemia Vera (PV). The Protagonist team is very pleased to see MIMRYLO reaching more patients around the world. #PolycythemiaVera #RareDisease #BloodCancer tinyurl.com/bderkhee

Post attachment
Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Sep 23

From local to global; very pleased to see ICOTYDE expanding its outreach. Best news for psoriasis patients who prefer a safe and effective needle-free treatment with the convenience of a once daily oral pill.

This week, the European Commission approved ICOTYDE™ (icotrokinra) for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Following approvals in the U.S. and China, European approval represents another important step in the global expansion of ICOTYDE — and further demonstrates the potential of targeted oral peptides to become an important new therapeutic option for patients worldwide. ema.europa.eu/en/medicines/h… #ICOTYDE #PeptideTherapeutics #PTGX

Business-News-Today.com avatar
⟳ Dinesh V. Patel, PhD retweeted
Business-News-Today.com@BNTBriefing·Sep 3

Takeda’s MIMRYLO approval unlocks $275m for Protagonist and a $1bn-plus PV bet business-news-today.com/take… $TAK $PTGX #Takeda #ProtagonistTherapeutics #MIMRYLO #Rusfertide #PolycythemiaVera #Hematology #FDA

Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Sep 1

And indeed, it does take a village, a busy village. Cheers!

The FDA approval of MIMRYLO™ (rusfertide) marks the culmination of more than a decade of work at Protagonist. Members of our team reflect on the journey and the patients, investigators, partners, and colleagues who helped make it possible. #PTGX #FDAApproval #PV

0:57
Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Sep 1

Great to see that #ICOTYDE is spreading its wings. Let the journey continue and touch and better as many lives as possible. Cheers!

China’s drug regulator has approved #ICOTYDE for moderate-to-severe plaque psoriasis. ICOTYDE continues to demonstrate the power of our peptide discovery platform and long-term collaboration with Johnson & Johnson. With approvals now in the U.S. and China, we look forward to the European Commission’s decision and the potential to bring this differentiated oral therapy to more patients globally. finance.yahoo.com/healthcare… #Psoriasis #IL23 #OralPeptides

Post attachment
Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Aug 24

It was great to join @SchwabNetwork last Friday. Thanks to the Schwab team for having me, and to the entire @ProtagonistTx team whose non-stop hard work continues to move our company forward and advance new medicines for patients.

On Friday, @ProtagonistCEO Dinesh Patel joined @SchwabNetwork #NextGenInvesting live to discuss peptides, obesity, and biopharma disruption. Watch it here: schwabnetwork.com/video/prot… #schwabnetwork

Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Aug 11

Very gratifying, humbling, satisfying, all at the same time. Thanks and Congrats to all involved for this wonderful recognition.

Today, ICOTYDE™ was nominated for the 2026 #PrixGalien USA Award for Best Pharmaceutical Product. This recognition by @GalienFdn highlights the scientific innovation behind the first and only FDA-approved targeted oral peptide designed to block the IL-23 receptor, bringing a novel plaque psoriasis treatment approach that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill. We’re gratified to see an innovation that began at Protagonist being recognized among this year's nominees and congratulate our colleagues at Johnson & Johnson, the Protagonist team, clinical investigators, and the patients who helped make this possible. #PeptideTherapeutics #DrugDiscovery #Innovation prnewswire.com/news-releases…

Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Jul 16

UNBELIEVABLE! ispot.tv/ad/gvER/icotyde-unb…

11,000 patients initiated. 18,000+ prescriptions written. 6,000 unique prescribers. More than 50% commercial coverage within 90 days. These are some of the metrics behind the early momentum of #ICOTYDE, as shared in Johnson & Johnson’s Q2 earnings call this morning. We are encouraged by the strong early momentum and excited about what lies ahead. Hear more from Johnson & Johnson’s Q2 earnings call: tinyurl.com/5hdypadm #PTGX #PeptideTherapeutics

0:21
Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Apr 30

Rusfertide, currently under a priority NDA review at FDA, is the outcome of a research program initiated at @ProtagonistTx in 2012. By opting-out of further co-development and co-commercialization, we place the company in an even stronger financial position while benefiting patients, our shareholders, and @TakedaPharma. Eagerly awaiting the potential approval in third quarter. Cheers!

Protagonist has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under our worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide. Rusfertide is now under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV). Read more: accessnewswire.com/newsroom/…

0:32
Dinesh V. Patel, PhD avatar
Dinesh V. Patel, PhD@ProtagonistCEO·Mar 21

Slow and steady does it. Humble beginnings from 2008 to now, but we are just not done yet. Repeat performance is the real charm. Cheers!

What a week for all of us at Protagonist! After celebrating the FDA Approval of ICOTYDE, we are thrilled to be recognized on the Nasdaq Tower in Times Square as a Fast 500 company. Ranking among the fastest-growing innovative companies in North America is a powerful validation of our innovation platform. To our customers, partners, and every member of the Protagonist family: This moment belongs to you. We’re just getting started. Looking forward to what's yet to come. #PTGX #NASDAQ #BayAreaFast500 #Biotech #Innovation

0:13
Vivek Patel avatar
⟳ Dinesh V. Patel, PhD retweeted
Vivek Patel@VDP83·Mar 19

Congrats dad (@ProtagonistCEO)! I'm *so* proud of what you and the @ProtagonistTx team have achieved. 13yrs end-to-end from R&D to full FDA approval for a new drug. It's inspiring.

Proud moment for Protagonist Therapeutics: today’s FDA approval of ICOTYDE marks 13 years of scientific dedication and operational excellence. A testament to our peptide platform and collaboration with Johnson & Johnson. Grateful to all who made this possible.